EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors

Davood Gheidari, Morteza Mehrdad, Foroozan Hoseini

Frontiers in Pharmacology · 02.07.2024 · 15

DOI: 10.3389/fphar.2024.1360226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.07.2024. Verfasst von Davood Gheidari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multiple sclerosis (MS) is an autoimmune and inflammatory disease that destroys the protective coating of central nervous system (CNS) nerve fibers and affects over 2.8 million people worldwide. Despite several studies on new therapeutic targets and lead compounds, MS disease has limited treatment options. This condition may be caused by a complicated interaction of environmental and genetic variables. Studies showed that MS-associated microglial cells’ increased MAPK ERK activity may cause CNS inflammation and oligodendrocyte damage. Thus, screening for lead compounds that inhibit MAPK ERK may protect brain cells and slow disease progression.

Methods

The study aims to discover compounds that may inhibit MAPK ERK as a novel approach for protecting the nervous system in managing MS. The study includes in silico methods, such as virtual screening, molecular docking, Density-functional theory (DFT) investigations (using the B3LYP/6–31++G(d,p) basis set in a gas phase environment), drug likeness scores, and molecular dynamic (MD) simulations. Results and Discussion: During the docking process with the MAPK ERK protein, it was shown that the ligand L 12 receptor had the best binding affinity, with a docking score of -6.18 kcal/mol. To investigate the stability of the binding, a 100 ns MD simulation was performed on the complex formed by the MAPK ERK protein and L 12 . The receptor-ligand combination exhibited significant stability throughout the duration of the MD simulation. Additionally, the pharmacokinetic and drug-likeness properties of these ligands suggest that they have the potential to be considered viable candidates for future development in MS management.

Schlagwörter

Stichwörter der Autor:innen

Diaza-adamantaneMAPKERKMD simulationmolecular dockingvirtual screening

Autor:innen und Institutionen

  • Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran.

Zitieren

APA

Gheidari, D., Mehrdad, M., & Hoseini, F. (2024). Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1360226

Vancouver

Gheidari D, Mehrdad M, Hoseini F. Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1360226

BibTeX
@article{Gheidari2024,
  author = {Gheidari, Davood and Mehrdad, Morteza and Hoseini, Foroozan},
  title = {Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1360226}
}
Kostenlos starten →